Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression.

Shoba Amarnath, PhD, James CM Wang, Paul R. Massey, James L. Riley, Bruce Levine, PhD, Carl H. June, MD, Jeffrey A. Medin, PhD, Daniel Fowler, MD

Blood (2009) 114 (22): 3580.

https://doi.org/10.1182/blood.V114.22.3580.3580

Published: 2009

Journal Articles

Pentostatin Facilitates Fully MHC-Disparate Murine Mini-Transplantation.

Jacopo Mariotti, Kaitlyn Ryan, Paul Massey, Nicole Buxhoeveden, Jason Foley, MS, MBA, Daniel Fowler, MD

Blood (2009) 114 (22): 3539.

https://doi.org/10.1182/blood.V114.22.3539.3539

Published: 2009

Journal Articles

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Saad Jamshed, MD, Daniel Fowler, MD, Sattva Neelapu, MD, Robert M. Dean, MD, Seth M Steinberg, PhD, Jeanne Odom, RN, Kelly Snow, RN, Ronald E Gress, MD, Michael R Bishop, MD

Blood (2008) 112 (11): 4328.

https://doi.org/10.1182/blood.V112.11.4328.4328

Published: 2008

Journal Articles

Pentostatin Is Advantageous Relative to Fludarabine for in Vivo Murine T Cell Depletion, Suppression of T Cell Cytokine Secretion, and Inhibition of HVGR

Jacopo Mariotti, Jason Foley, MS, MBA, Kaitlyn Ryan, Nicole Buxhoeveden, Daniel Fowler, MD

Blood (2008) 112 (11): 3483.

https://doi.org/10.1182/blood.V112.11.3483.3483

Published: 2008

Journal Articles

Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

Nancy M. Hardy, MD, Frances Hakim, PhD, Seth Steinberg, PhD, Michael Krumlauf, Rebecca Babb, Jeanne Odom, Daniel Fowler, MD, Ronald Gress, MD, Michael R. Bishop, MD

Blood (2006) 108 (11): 2871.

https://doi.org/10.1182/blood.V108.11.2871.2871

Published: 2006

Journal Articles

Early Reconstitution of Natural Killer Cells Following Non-Myeloablative Hematopoietic Stem Cell Transplantation Predicts the Development of Acute Graft-Versus-Host Disease.

Michael Boyiadzis, MD, MHSc, Frances T. Hakim, PhD, Sarfraz A. Memon, MD, Robert Dean, MD, Daniel Fowler, MD, Ronald E. Gress, MD, Michael R. Bishop, MD

Blood (2006) 108 (11): 2882.

https://doi.org/10.1182/blood.V108.11.2882.2882

Published: 2006

Journal Articles

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Robert M. Dean, MD, Daniel Fowler, MD, Wyndham H. Wilson, MD, PhD, Frances Hakim, PhD, Seth Steinberg, PhD, Jeanne Odom, RN, Catherine Chow, MD, Claude Sportes, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD, Nancy M. Hardy, MD, Ronald Gress, MD, Michael R. Bishop

Blood (2006) 108 (11): 317.

https://doi.org/10.1182/blood.V108.11.317.317

Published: 2006

Journal Articles

Early Recovery of Thymus-Derived Naïve T Cells in Pediatric Patients (pts) Treated with Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NMSCT) for Cancer.

Terry J. Fry, MD, Alison R. Rager, Frances Hakim, PhD, Cynthia Love, Paula Layton, Daniel Fowler, MD, Michael R. Bishop, MD, Ronald Gress, MD, Crystal L. Mackall, MD, Alan S. Wayne, MD

Blood (2006) 108 (11): 310.

https://doi.org/10.1182/blood.V108.11.310.310

Published: 2006

Journal Articles

IL-15 Plays a Critical Role in CD8+ T-Cell Recovery after Allogeneic Transplantation.

Frances T. Hakim, PhD, Kenton Allen, BA, Jesse M. Carson, BA, Michael Boyiadzis, MD, Sarfraz A. Memon, MD, Robert Dean, MD, Jeanne Odom, R.N., Alan Wayne, MD, Daniel Fowler, MD, Michael R. Bishop, MD, Ronald E. Gress, MD

Blood (2005) 106 (11): 1414.

https://doi.org/10.1182/blood.V106.11.1414.1414

Published: 2005

Journal Articles

Pilot Clinical Trial of Adoptive Immunotherapy with Chimeric, Co-Stimulated Tumor-Infiltrating Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation.

Nancy M. Hardy, MD, Vicki Fellowes, Jacopo Mariotti, MD, Charles Carter, Carl June4, MD, Bruce L. Levine4, PhD, Frances Hakim, PhD, Robert Vonderheide4, MD, DPhil, Ronald Gress, MD, Elizabeth J. Read, MD, Daniel Fowler, MD, Michael R. Bishop, MD

Blood (2005) 106 (11): 5407.

https://doi.org/10.1182/blood.V106.11.5407.5407

Published: 2005

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (SCT) with Pre-Transplant Targeted Immune Depletion Results in Rapid Full Donor Engraftment in Pediatric Patients with Malignancy.

Terry J. Fry, MD, Teresa Cardesa-Salzman, MD, Frances Hakim, PhD, Cynthia Love, R.N., BSN., Paula Layton, R.N., BSN, Ronald Gress, MD, Daniel Fowler, MD, Michael R. Bishop, MD, Crystal L. Mackall, MD, Alan S. Wayne, MD

Blood (2005) 106 (11): 3672.

https://doi.org/10.1182/blood.V106.11.3672.3672

Published: 2005

NARROW

PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression.

Pentostatin Facilitates Fully MHC-Disparate Murine Mini-Transplantation.

EPOCH-F: A Novel Salvage Regimen for Multiple Myeloma Prior to Reduced-Intensity Allogeneic Stem Cell Transplantation

Pentostatin Is Advantageous Relative to Fludarabine for in Vivo Murine T Cell Depletion, Suppression of T Cell Cytokine Secretion, and Inhibition of HVGR

Ex-Vivo Reduction of Allograft T Cell Dose Does Not Prevent Acute Graft-vs-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation.

Early Reconstitution of Natural Killer Cells Following Non-Myeloablative Hematopoietic Stem Cell Transplantation Predicts the Development of Acute Graft-Versus-Host Disease.

Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST).

Early Recovery of Thymus-Derived Naïve T Cells in Pediatric Patients (pts) Treated with Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NMSCT) for Cancer.

IL-15 Plays a Critical Role in CD8+ T-Cell Recovery after Allogeneic Transplantation.

Pilot Clinical Trial of Adoptive Immunotherapy with Chimeric, Co-Stimulated Tumor-Infiltrating Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation.

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (SCT) with Pre-Transplant Targeted Immune Depletion Results in Rapid Full Donor Engraftment in Pediatric Patients with Malignancy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only